These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 27664101)
41. Death by Suicide in Graves' Disease and Graves' Orbitopathy: A Nationwide Danish Register Study. Ferløv-Schwensen C; Brix TH; Hegedüs L Thyroid; 2017 Dec; 27(12):1475-1480. PubMed ID: 29084476 [TBL] [Abstract][Full Text] [Related]
42. Thyroid eye disease or Graves' orbitopathy: What name to use, and why it matters. Wagner LH; Bradley EA; Tooley AA; Ren Y; Rachmasari KN; Stan MN Front Endocrinol (Lausanne); 2022; 13():1083886. PubMed ID: 36518254 [TBL] [Abstract][Full Text] [Related]
43. Graves' ophthalmopathy in patients treated with radioiodine 131-I. Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402 [TBL] [Abstract][Full Text] [Related]
44. Survey of common practices among oculofacial surgeons in the Asia-Pacific region: Graves' orbitopathy. Sundar G; Chiam N; Lun K; Koh V Orbit; 2014 Oct; 33(5):319-25. PubMed ID: 25121573 [TBL] [Abstract][Full Text] [Related]
45. [Novel treatment opportunities in Graves' orbitopathy]. Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914 [TBL] [Abstract][Full Text] [Related]
46. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy. Bednarczuk T; Schomburg L Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133 [TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics and the treatment modalities of Graves' orbitopathy in a tertiary referral center in Turkey: changes over two decades. Ozturk M; Konuk O; Tarlan B; Yalcın MM; Arıbas YK; Toruner FB; Unal M; Ayvaz G Int Ophthalmol; 2023 Feb; 43(2):643-653. PubMed ID: 36030455 [TBL] [Abstract][Full Text] [Related]
48. Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study. Perros P; Žarković MP; Panagiotou GC; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi AM; Nardi M; Brix TH; Covelli D; Daumerie C; Eckstein AK; Fichter N; Ćirić S; Hegedüs L; Kahaly GJ; Konuk O; Lareida JJ; Okosieme OE; Leo M; Mathiopoulou L; Clarke L; Menconi F; Morris DS; Orgiazzi J; Pitz S; Salvi M; Muller I; Knežević M; Wiersinga WM; Currò N; Dayan CM; Marcocci C; Marinò M; Möller L; Pearce SH; Törüner F; Bernard M; J Endocrinol Invest; 2020 Dec; 43(12):1717-1722. PubMed ID: 32474767 [TBL] [Abstract][Full Text] [Related]
49. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy. Riedl M; Kuhn A; Krämer I; Kolbe E; Kahaly GJ J Endocrinol Invest; 2016 Jun; 39(6):687-94. PubMed ID: 26886940 [TBL] [Abstract][Full Text] [Related]
51. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414 [TBL] [Abstract][Full Text] [Related]
52. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy? Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539 [TBL] [Abstract][Full Text] [Related]
53. Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease. Lanzolla G; Marinò M; Marcocci C Front Endocrinol (Lausanne); 2020; 11():608428. PubMed ID: 33574798 [TBL] [Abstract][Full Text] [Related]